Canada markets closed

Orphazyme A/S (ORPHY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0800+0.0788 (+6,566.67%)
At close: 12:07PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0012
BidN/A x N/A
AskN/A x N/A
Day's Range0.0200 - 0.1000
52 Week Range0.0002 - 7.4800
Avg. Volume85,916
Market Cap2.825M
Beta (5Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)-2.5370
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
  • GlobeNewswire

    Resolutions passed at the Annual General Meeting

    Orphazyme A/SCompany announcementNo. 33/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, June 29, 2022 – Orphazyme A/S (ORPHA.CO) (the “Company”), today held its Annual General Meeting, at which the Annual General Meeting: Financial year 2021 and 2022 Took note of the Board of Directors’ report on the Company’s activities in the past financial year;Adopted the Company’s Annual Report 2021;Adopted that the loss related to the financial year 2021 is carried forward;Appr

  • GlobeNewswire

    Updated notice to holders of ADSs regarding termination of Deposit Agreement

    Orphazyme A/SCompany announcement No. 32/2022www.orphazyme.comCompany Registration No. 32266355 NOTICE TO HOLDERS OF AMERICAN DEPOSITARY SHARES (“ADSs”) EVIDENCED BYAMERICAN DEPOSITARY RECEIPTS (“ADRs”) REPRESENTING DEPOSITED COMMON SHARES OF:ORPHAZYME A/S ONE ADS REPRESENTS ONE COMMON SHARECUSIP: 687305102 AND UNDERLYING ISIN: DK0060910917 Copenhagen, Denmark, June 20, 2022 – Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), hereby provides notice to holders of American Depositary Shares

  • GlobeNewswire

    Correction: Orphazyme Announces Publication of 2021 Financial Results and Annual Report

    Orphazyme A/SCompany announcementNo. 30/2022 Annual Company Registration No. 32266355 [Correction: Hereby including the ESEF versions] Copenhagen, Denmark, June 7, 2022 – Orphazyme A/S (ORPHA.CO) (“Orphazyme” or the “Company”), today reports its financial results for the period from January 1, 2021, to December 31, 2021, and publishes its Annual Report. In 2021, and until recently, the primary focus of Orphazyme was on seeking marketing authorization in the United States